Annual General Meeting in ALK-Abelló A/S on 13 March 2025

GlobeNewswire

02-19

ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.

ALK-Abelló A/S

For further information please contact:

Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525

Media: Maiken Riise Andersen, tel. +45 5054 1434

About ALK
ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.

Attachment

ALK_AGM_2025_Company release_02_2025

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2512610796"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2512610796\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2512610796?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-19 21:46","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2512610796","market":"hk","top_or_hot":-1,"title":"Annual General Meeting in ALK-Abelló A/S on 13 March 2025","media":"GlobeNewswire","content":"<html><body><p>ALK (<i>ALKB:DC / OMX: ALK B / AKBLF</i>): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. </p> <p><b>ALK-Abelló A/S</b></p> <p><b>For further information please contact:</b></p> <p><em>Investor Relations</em>: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525</p> <p><i>Media</i>: Maiken Riise Andersen, tel. +45 5054 1434</p> <p><b><i>About ALK</i></b><br/><i>ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net</i><i>.</i></p> <p>\n<strong>Attachment</strong>\n</p>\n<ul>\n<li>\nALK_AGM_2025_Company release_02_2025\n</li>\n</ul>\n<br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/Y2VmY2I1ZTAtY2Q3ZC00MzJiLThlNTYtNWNmNjRlNTNhNzRlLTEwMTM4MDQ=/tiny/ALK-Abello.png\"/></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta content=\"text/html; charset=utf-8\" http-equiv=\"Content-Type\"/>\n<meta content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\" name=\"viewport\"/>\n<meta content=\"telephone=no,email=no,address=no\" name=\"format-detection\"/>\n<title>Annual General Meeting in ALK-Abelló A/S on 13 March 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnual General Meeting in ALK-Abelló A/S on 13 March 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1016364462\">\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a);background-size:cover;\"></div>\n<div class=\"h-content\">\n<p class=\"h-name\">GlobeNewswire </p>\n<p class=\"h-time smaller\">2025-02-19 21:46</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ALK (<i>ALKB:DC / OMX: ALK B / AKBLF</i>): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached. </p> <p><b>ALK-Abelló A/S</b></p> <p><b>For further information please contact:</b></p> <p><em>Investor Relations</em>: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525</p> <p><i>Media</i>: Maiken Riise Andersen, tel. +45 5054 1434</p> <p><b><i>About ALK</i></b><br/><i>ALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net</i><i>.</i></p> <p>\n<strong>Attachment</strong>\n</p>\n<ul>\n<li>\nALK_AGM_2025_Company release_02_2025\n</li>\n</ul>\n<br/><img referrerpolicy=\"no-referrer-when-downgrade\" src=\"https://ml-eu.globenewswire.com/media/Y2VmY2I1ZTAtY2Q3ZC00MzJiLThlNTYtNWNmNjRlNTNhNzRlLTEwMTM4MDQ=/tiny/ALK-Abello.png\"/>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ALK","symbol_name":"阿拉斯加航空集團有限公司","start_time":0,"source_url":"https://www.globenewswire.com/news-release/2025/02/19/3028793/0/en/Annual-General-Meeting-in-ALK-Abell%C3%B3-A-S-on-13-March-2025.html","article_id":"2512610796","we_media_id":"1016364462","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2512610796","pubTimestamp":1739972760,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"GlobeNewswire","introduction":"Share your news with media, investors, and consumers with targeted distribution options from one of the world’s largest and most trusted newswires.","home_visible":1,"id":"1016364462","head_image":"https://static.tigerbbs.com/31bb960c88eab45f27ccc9fce75dee9a"},"summary":"ALK : The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM  at ALK-Abelló A/S, Bge Allé 1, 2970 Hrsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.  ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hrsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ALK":"阿拉斯加航空集团有限公司","BK4008":"航空公司","BK4585":"ETF&股票定投概念","BK4588":"碎股","CET":"Central Securities Corp","BK4500":"航空公司"},"translate_title":"2025年3月13日在ALK-AbellóA/S举行的年度股东大会","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALK":1,"CET":1},"content_text":"ALK (ALKB:DC / OMX: ALK B / AKBLF): The Annual General Meeting of ALK-Abelló A/S will take place on Thursday, 13 March 2025 at 4:00 PM (CET) at ALK-Abelló A/S, Bøge Allé 1, 2970 Hørsholm, Denmark. The agenda of the meeting including the complete proposals from the Board of Directors to the AGM is attached.  ALK-Abelló A/S For further information please contact: Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525 Media: Maiken Riise Andersen, tel. +45 5054 1434 About ALKALK is a global specialty pharmaceutical company focused on allergy and allergic asthma. It markets allergy immunotherapy treatments and other products and services for people with allergy and allergy doctors. Headquartered in Hørsholm, Denmark, ALK employs around 2,800 people worldwide and is listed on Nasdaq Copenhagen. Find more information at www.alk.net. \nAttachment\n\n\n\nALK_AGM_2025_Company release_02_2025","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}